In vitro activity of BMY-28100, a new oral cephalosporin |
| |
| Authors: | C W Norden K Niederriter |
| |
| Affiliation: | Montefiore Hospital, Department of Medicine, University of Pittsburgh, School of Medicine, Pa. |
| |
| Abstract: | BMY-28100 is a new orally absorbed cephalosporin whose in vitro activity was compared with that of cefaclor. BMY-28100 was more active against Staphylococcus aureus and Haemophilus influenzae than was cefaclor. In addition, there was only a small rise in MIC50 and MIC90 values for BMY-28100 when the inoculum size was increased 100- or 10,000-fold. In contrast, MIC50 and MIC90 values increased significantly for cefaclor with similar increases in inoculum size. These data suggest that BMY-28100 may be a promising agent to test for oral administration in infections caused by S. aureus and H. influenzae. |
| |
| Keywords: | |
|
|
